Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy

Frank Arnold; H. Brem; G. Tamavokopulis; D. Tsakayannis; I. Gresser; A. Budson; J. Folkman; Tzafra Cohen; Hela Gitay-Goren; Gera Neufeld; Ben Zion Levi; George Cherry; Anne Eichman; Christophe Marcelle; Christiane Bréant; Nicole M. LeDouarin; Nam D. Tran; Vicky L. Y. Wong; James Bready; Judith Berliner; Mark Fisher; O. Hadjiconti; S. Papaioannou; G. C. Haralabopoulos; I. Demopoulos; M. E. Maragoudakis; George C. Haralabopoulos; Nikos E. Tsopanoglou; Eva Pipili-Synetos; E. Keshet; D. Shweiki; E. Bacharach; A. Itin; S. Banai; M. A. Konerding; C. van Ackern; B. Klapthor; F. Steinberg; M. Lehmann; P. Koolwijk; W. J. A. de Vree; C. Zurcher; V. W. M. van Hinsbergh; Jerzy Krupinski; Jozef Kaluza; E. Missirli; M. Bastaki; G. Karakiulakis; D. E. Morales; D. S. Grant; S. Maheshwari; D. Bhartiya; M. C. Cid; H. K. Kleinman; W. H. Schnaper; E. Papadimitriou; B. R. Unsworth; P. I. Lelkes; P. Rooney; I. Smith; S. Kumar; Cliff Stevens; Suzanne Harley; Rajdip Marok; Tulin Sahinoglu; Stewart Abbot; David Blake; Maureen Dougher-Vermazen; Denis Gospodarowicz; Bruce I. Terman

doi:10.1007/978-1-4757-9188-4_37

Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy

Frank Arnold, H. Brem, G. Tamavokopulis, D. Tsakayannis, I. Gresser, A. Budson, J. Folkman, Tzafra Cohen, Hela Gitay-Goren, Gera Neufeld, Ben Zion Levi, George Cherry, Anne Eichman, Christophe Marcelle, Christiane Bréant, Nicole M. LeDouarin, Nam D. Tran, Vicky L. Y. Wong, James Bready, Judith BerlinerMark Fisher, O. Hadjiconti, S. Papaioannou, G. C. Haralabopoulos, I. Demopoulos, M. E. Maragoudakis, George C. Haralabopoulos, Nikos E. Tsopanoglou, Eva Pipili-Synetos, E. Keshet, D. Shweiki, E. Bacharach, A. Itin, S. Banai, M. A. Konerding, C. van Ackern, B. Klapthor, F. Steinberg, M. Lehmann, P. Koolwijk, W. J. A. de Vree, C. Zurcher, V. W. M. van Hinsbergh, Jerzy Krupinski, Jozef Kaluza, E. Missirli, M. Bastaki, G. Karakiulakis, D. E. Morales, D. S. Grant, S. Maheshwari, D. Bhartiya, M. C. Cid, H. K. Kleinman, W. H. Schnaper, E. Papadimitriou, B. R. Unsworth, P. I. Lelkes, P. Rooney, I. Smith, S. Kumar, Cliff Stevens, Suzanne Harley, Rajdip Marok, Tulin Sahinoglu, Stewart Abbot, David Blake, Maureen Dougher-Vermazen, Denis Gospodarowicz, Bruce I. Terman

Institute for Medical Research Israel-Canada (IMRIC)

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The propensity of tumours to generate resistant clones is a major barrier to cytotoxic and hormone therapy. The vasculature of malignancies is a more appealing target, since tumour endothelial cells are not known to be tranformed or subject to somatic mutation or random phenotypic variation. Thus an effective anti-angiogenic therapy need not be vitiated by the acquisition of resistance. Although several antiangiogenic agents have been described and used in experimental models, there remain severe problems about optimising their use and about setting up informative clinical trials. These difficulties arise predominantly because of the “invisible” nature of tumour angiogenesis.

Original language	American English
Title of host publication	Angiogenesis: Molecular Biology, Clinical Aspects
Editors	Michael E. Maragoudakis, Pietro M. Gullino, Peter I. Lelkes
Place of Publication	Boston, MA
Publisher	Springer US; Imprint: Springer
Pages	333-358
Number of pages	26
ISBN (Print)	978-1-4757-9188-4
DOIs	https://doi.org/10.1007/978-1-4757-9188-4_37
State	Published - 1994

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-4757-9188-4_37

Cite this

Arnold, F., Brem, H., Tamavokopulis, G., Tsakayannis, D., Gresser, I., Budson, A., Folkman, J., Cohen, T., Gitay-Goren, H., Neufeld, G., Levi, B. Z., Cherry, G., Eichman, A., Marcelle, C., Bréant, C., LeDouarin, N. M., Tran, N. D., Wong, V. L. Y., Bready, J., ... Terman, B. I. (1994). Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy. In M. E. Maragoudakis, P. M. Gullino, & P. I. Lelkes (Eds.), Angiogenesis: Molecular Biology, Clinical Aspects (pp. 333-358). Springer US; Imprint: Springer. https://doi.org/10.1007/978-1-4757-9188-4_37

@inbook{2f294a64ed8b487ebc3ec5731a311c58,

title = "Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy",

abstract = "The propensity of tumours to generate resistant clones is a major barrier to cytotoxic and hormone therapy. The vasculature of malignancies is a more appealing target, since tumour endothelial cells are not known to be tranformed or subject to somatic mutation or random phenotypic variation. Thus an effective anti-angiogenic therapy need not be vitiated by the acquisition of resistance. Although several antiangiogenic agents have been described and used in experimental models, there remain severe problems about optimising their use and about setting up informative clinical trials. These difficulties arise predominantly because of the “invisible” nature of tumour angiogenesis.",

author = "Frank Arnold and H. Brem and G. Tamavokopulis and D. Tsakayannis and I. Gresser and A. Budson and J. Folkman and Tzafra Cohen and Hela Gitay-Goren and Gera Neufeld and Levi, \{Ben Zion\} and George Cherry and Anne Eichman and Christophe Marcelle and Christiane Br{\'e}ant and LeDouarin, \{Nicole M.\} and Tran, \{Nam D.\} and Wong, \{Vicky L. Y.\} and James Bready and Judith Berliner and Mark Fisher and O. Hadjiconti and S. Papaioannou and Haralabopoulos, \{G. C.\} and I. Demopoulos and Maragoudakis, \{M. E.\} and Haralabopoulos, \{George C.\} and Tsopanoglou, \{Nikos E.\} and Eva Pipili-Synetos and E. Keshet and D. Shweiki and E. Bacharach and A. Itin and S. Banai and Konerding, \{M. A.\} and \{van Ackern\}, C. and B. Klapthor and F. Steinberg and M. Lehmann and P. Koolwijk and \{de Vree\}, \{W. J. A.\} and C. Zurcher and \{van Hinsbergh\}, \{V. W. M.\} and Jerzy Krupinski and Jozef Kaluza and E. Missirli and M. Bastaki and G. Karakiulakis and Morales, \{D. E.\} and Grant, \{D. S.\} and S. Maheshwari and D. Bhartiya and Cid, \{M. C.\} and Kleinman, \{H. K.\} and Schnaper, \{W. H.\} and E. Papadimitriou and Unsworth, \{B. R.\} and Lelkes, \{P. I.\} and P. Rooney and I. Smith and S. Kumar and Cliff Stevens and Suzanne Harley and Rajdip Marok and Tulin Sahinoglu and Stewart Abbot and David Blake and Maureen Dougher-Vermazen and Denis Gospodarowicz and Terman, \{Bruce I.\}",

year = "1994",

doi = "10.1007/978-1-4757-9188-4\_37",

language = "American English",

isbn = "978-1-4757-9188-4",

pages = "333--358",

editor = "Maragoudakis, \{Michael E.\} and Gullino, \{Pietro M.\} and Lelkes, \{Peter I.\}",

booktitle = "Angiogenesis: Molecular Biology, Clinical Aspects",

publisher = "Springer US; Imprint: Springer",

}

Arnold, F, Brem, H, Tamavokopulis, G, Tsakayannis, D, Gresser, I, Budson, A, Folkman, J, Cohen, T, Gitay-Goren, H, Neufeld, G, Levi, BZ, Cherry, G, Eichman, A, Marcelle, C, Bréant, C, LeDouarin, NM, Tran, ND, Wong, VLY, Bready, J, Berliner, J, Fisher, M, Hadjiconti, O, Papaioannou, S, Haralabopoulos, GC, Demopoulos, I, Maragoudakis, ME, Haralabopoulos, GC, Tsopanoglou, NE, Pipili-Synetos, E, Keshet, E, Shweiki, D, Bacharach, E, Itin, A, Banai, S, Konerding, MA, van Ackern, C, Klapthor, B, Steinberg, F, Lehmann, M, Koolwijk, P, de Vree, WJA, Zurcher, C, van Hinsbergh, VWM, Krupinski, J, Kaluza, J, Missirli, E, Bastaki, M, Karakiulakis, G, Morales, DE, Grant, DS, Maheshwari, S, Bhartiya, D, Cid, MC, Kleinman, HK, Schnaper, WH, Papadimitriou, E, Unsworth, BR, Lelkes, PI, Rooney, P, Smith, I, Kumar, S, Stevens, C, Harley, S, Marok, R, Sahinoglu, T, Abbot, S, Blake, D, Dougher-Vermazen, M, Gospodarowicz, D & Terman, BI 1994, Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy. in ME Maragoudakis, PM Gullino & PI Lelkes (eds), Angiogenesis: Molecular Biology, Clinical Aspects. Springer US; Imprint: Springer, Boston, MA, pp. 333-358. https://doi.org/10.1007/978-1-4757-9188-4_37

Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy. / Arnold, Frank; Brem, H.; Tamavokopulis, G. et al.
Angiogenesis: Molecular Biology, Clinical Aspects. ed. / Michael E. Maragoudakis; Pietro M. Gullino; Peter I. Lelkes. Boston, MA: Springer US; Imprint: Springer, 1994. p. 333-358.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy

AU - Arnold, Frank

AU - Brem, H.

AU - Tamavokopulis, G.

AU - Tsakayannis, D.

AU - Gresser, I.

AU - Budson, A.

AU - Folkman, J.

AU - Cohen, Tzafra

AU - Gitay-Goren, Hela

AU - Neufeld, Gera

AU - Levi, Ben Zion

AU - Cherry, George

AU - Eichman, Anne

AU - Marcelle, Christophe

AU - Bréant, Christiane

AU - LeDouarin, Nicole M.

AU - Tran, Nam D.

AU - Wong, Vicky L. Y.

AU - Bready, James

AU - Berliner, Judith

AU - Fisher, Mark

AU - Hadjiconti, O.

AU - Papaioannou, S.

AU - Haralabopoulos, G. C.

AU - Demopoulos, I.

AU - Maragoudakis, M. E.

AU - Haralabopoulos, George C.

AU - Tsopanoglou, Nikos E.

AU - Pipili-Synetos, Eva

AU - Keshet, E.

AU - Shweiki, D.

AU - Bacharach, E.

AU - Itin, A.

AU - Banai, S.

AU - Konerding, M. A.

AU - van Ackern, C.

AU - Klapthor, B.

AU - Steinberg, F.

AU - Lehmann, M.

AU - Koolwijk, P.

AU - de Vree, W. J. A.

AU - Zurcher, C.

AU - van Hinsbergh, V. W. M.

AU - Krupinski, Jerzy

AU - Kaluza, Jozef

AU - Missirli, E.

AU - Bastaki, M.

AU - Karakiulakis, G.

AU - Morales, D. E.

AU - Grant, D. S.

AU - Maheshwari, S.

AU - Bhartiya, D.

AU - Cid, M. C.

AU - Kleinman, H. K.

AU - Schnaper, W. H.

AU - Papadimitriou, E.

AU - Unsworth, B. R.

AU - Lelkes, P. I.

AU - Rooney, P.

AU - Smith, I.

AU - Kumar, S.

AU - Stevens, Cliff

AU - Harley, Suzanne

AU - Marok, Rajdip

AU - Sahinoglu, Tulin

AU - Abbot, Stewart

AU - Blake, David

AU - Dougher-Vermazen, Maureen

AU - Gospodarowicz, Denis

AU - Terman, Bruce I.

PY - 1994

Y1 - 1994

N2 - The propensity of tumours to generate resistant clones is a major barrier to cytotoxic and hormone therapy. The vasculature of malignancies is a more appealing target, since tumour endothelial cells are not known to be tranformed or subject to somatic mutation or random phenotypic variation. Thus an effective anti-angiogenic therapy need not be vitiated by the acquisition of resistance. Although several antiangiogenic agents have been described and used in experimental models, there remain severe problems about optimising their use and about setting up informative clinical trials. These difficulties arise predominantly because of the “invisible” nature of tumour angiogenesis.

AB - The propensity of tumours to generate resistant clones is a major barrier to cytotoxic and hormone therapy. The vasculature of malignancies is a more appealing target, since tumour endothelial cells are not known to be tranformed or subject to somatic mutation or random phenotypic variation. Thus an effective anti-angiogenic therapy need not be vitiated by the acquisition of resistance. Although several antiangiogenic agents have been described and used in experimental models, there remain severe problems about optimising their use and about setting up informative clinical trials. These difficulties arise predominantly because of the “invisible” nature of tumour angiogenesis.

U2 - 10.1007/978-1-4757-9188-4_37

DO - 10.1007/978-1-4757-9188-4_37

M3 - Chapter

SN - 978-1-4757-9188-4

SP - 333

EP - 358

BT - Angiogenesis: Molecular Biology, Clinical Aspects

A2 - Maragoudakis, Michael E.

A2 - Gullino, Pietro M.

A2 - Lelkes, Peter I.

PB - Springer US; Imprint: Springer

CY - Boston, MA

ER -

Some Problems of Trial Design for Anti-Angiogenic Agents in Cancer Therapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this